Mesoblast Limited – NASDAQ:MESO
Founder-led company
Mesoblast Limited stock price today
$15.5
-2.03
-11.58%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Mesoblast Limited stock price monthly change
+117.76%
month
Mesoblast Limited stock price quarterly change
+117.76%
quarter
Mesoblast Limited stock price yearly change
+1508.26%
year
Mesoblast Limited key metrics
Market Cap | 1.79B |
Enterprise value | 563.38M |
P/E | -5.77 |
EV/Sales | 68.84 |
EV/EBITDA | -8.32 |
Price/Sales | 63.45 |
Price/Book | 1.03 |
PEG ratio | -0.76 |
EPS | -0.85 |
Revenue | 8.31M |
EBITDA | -68.02M |
Income | -83.27M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -1084.81% |
Oper. margin | -949.15% |
Gross margin | 0% |
EBIT margin | -949.15% |
EBITDA margin | -818.27% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeMesoblast Limited stock price history
Mesoblast Limited stock forecast
Mesoblast Limited financial statements
| Mar 2022 | 2.01M | -21.30M | -1059.27% |
|---|---|---|---|
| Jun 2022 | 2.22M | -21.45M | -964.7% |
| Mar 2023 | 1.93M | -18.6M | -959.26% |
| Jun 2023 | 2.13M | -21.91M | -1024.73% |
| Sep 2027 | 3.46M | -263.72M | -7607.42% |
|---|---|---|---|
| Dec 2027 | 2.1M | -226.04M | -10764.13% |
| Mar 2028 | 2.13M | -268.02M | -12526.82% |
| Jun 2028 | 2.38M | -235.73M | -9890.76% |
Analysts Price target
Financials & Ratios estimates
| 2023-08-30 | -0.32 | -0.28 |
|---|
| Sep 2022 | 684496000 | 161.68M | 23.62% |
|---|---|---|---|
| Dec 2022 | 668060000 | 168.05M | 25.16% |
| Mar 2023 | 650441000 | 168.27M | 25.87% |
| Jun 2023 | 669415000 | 167.57M | 25.03% |
| Jun 2022 | -13.89M | -47K | -2.21M |
|---|---|---|---|
| Mar 2023 | -16.25M | 27K | -2.54M |
| Jun 2023 | -16.27M | 16K | 38.75M |
| Mar 2024 | 0 | 19K | 11.66M |
Mesoblast Limited alternative data
| Aug 2023 | 77 |
|---|---|
| Sep 2023 | 77 |
| Oct 2023 | 83 |
| Nov 2023 | 83 |
| Dec 2023 | 83 |
| Jan 2024 | 83 |
| Feb 2024 | 83 |
| Mar 2024 | 83 |
| Apr 2024 | 83 |
| May 2024 | 83 |
| Jun 2024 | 83 |
| Jul 2024 | 83 |
Mesoblast Limited other data
0.21%
-0.17%
of MESO is owned by hedge funds
1.56M
-1.11M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q2 2024 29 Feb 2024 | Q2 2024 Earnings Call Transcript |
| Q4 2023 30 Aug 2023 | Q4 2023 Earnings Call Transcript |
| Q3 2023 25 May 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Mar 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) (1957) Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director | $1,050,000 |
-
What's the price of Mesoblast Limited stock today?
One share of Mesoblast Limited stock can currently be purchased for approximately $15.5.
-
When is Mesoblast Limited's next earnings date?
Unfortunately, Mesoblast Limited's (MESO) next earnings date is currently unknown.
-
Does Mesoblast Limited pay dividends?
No, Mesoblast Limited does not pay dividends.
-
How much money does Mesoblast Limited make?
Mesoblast Limited has a market capitalization of 1.79B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 21.32% to 5.9M US dollars. Mesoblast Limited made a loss 87.96M US dollars in net income (profit) last year or -$0.28 on an earnings per share basis.
-
What is Mesoblast Limited's stock symbol?
Mesoblast Limited is traded on the NASDAQ under the ticker symbol "MESO".
-
What is Mesoblast Limited's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Mesoblast Limited?
Shares of Mesoblast Limited can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Mesoblast Limited's key executives?
Mesoblast Limited's management team includes the following people:
- Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons) Founder, Chief Executive Officer, MD, Chairman of Scientific Advisory Board & Executive Director(age: 68, pay: $1,050,000)
-
Is Mesoblast Limited founder-led company?
Yes, Mesoblast Limited is a company led by its founder Dr. Silviu Itescu FACP, FACRA, FRACP, MBBS (Hons).
-
How many employees does Mesoblast Limited have?
As Jul 2024, Mesoblast Limited employs 83 workers.
-
When Mesoblast Limited went public?
Mesoblast Limited is publicly traded company for more then 15 years since IPO on 20 Jan 2010.
-
What is Mesoblast Limited's official website?
The official website for Mesoblast Limited is mesoblast.com.
-
Where are Mesoblast Limited's headquarters?
Mesoblast Limited is headquartered at 55 Collins Street, Melbourne, VIC.
-
How can i contact Mesoblast Limited?
Mesoblast Limited's mailing address is 55 Collins Street, Melbourne, VIC and company can be reached via phone at +61 3 9639 6036.
Mesoblast Limited company profile:
Mesoblast Limited
mesoblast.comExchange:
NASDAQ
Full time employees:
73
Industry:
Biotechnology
Sector:
Healthcare
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
55 Collins Street
Melbourne, VIC 3000
Melbourne, VIC 3000
CIK: 0001345099
ISIN: US5907174016
CUSIP: 590717104
